Search Results - "Hofman, M.S"

The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable by Barber, T.W, Hofman, M.S, Thomson, B.N.J, Hicks, R.J

“…Abstract Aims To assess the clinical utility of peptide receptor chemoradionuclide therapy (PRCRT) using177 Lu-octreotate (LuTate) with concurrent 5FU…”
Get full text

Age and Gender Differences in the Distribution of Proliferating Bone Marrow in Adults Measured by FLT-PET/CT Imaging With Potential Application for Radiation Therapy Planning by Campbell, B.A, Callahan, J, Bressel, M, Simeons, N, Everitt, S, Hofman, M.S, Hicks, R, Burbury, K, MacManus, M.P

Get full text

PO-0955: Comparing lung function changes between serial CT-ventilation and Galligas Ventilation PET/CT by Kipritidis, J, Siva, S, Hofman, M.S, Callahan, J, Hardcastle, N, Keall, P.J

Get full text

EP-1530: Limitations of deformable image registration in 4D PET V/Q imaging for functional assessment in lung radiotherapy by Hardcastle, N, Hofman, M.S, Hicks, R.J, Callahan, J, Kron, T, MacManus, M.P, Ball, D.L, Jackson, P, Siva, S

Get full text

Imaging in follicular NHL by Hofman, M.S., MBBS, FRACP, Hicks, R.J., MBBS, MD, FRACP

“…Imaging contributes to management of follicular lymphoma (FL) through guiding biopsy, determining disease stage and assessing therapeutic response. Molecular…”
Get full text

Combined Biology-Guided Radiotherapy and Lutetium PSMA Treatment in Metastatic Prostate Cancer by Gaudreault, M., Chang, D., Hardcastle, N., Jackson, P., Kron, T., Hofman, M.S., Siva, S.

Get full text

High Rate of Abscopal Regression of Follicular Lymphoma after Low Dose Involved-Site Radiation Therapy Detected by FDG-PET Scans by MacManus, M.P., Hofman, M.S., Hicks, R., Campbell, B.A., Wirth, A., Seymour, J.F., Burbury, K.

Get full text

Next generation radiotheranostics promoting precision medicine by Pomykala, K.L., Hadaschik, B.A., Sartor, O., Gillessen, S., Sweeney, C.J., Maughan, T., Hofman, M.S., Herrmann, K.

“…Radiotheranostics is a field of rapid growth with some approved treatments including 131I for thyroid cancer, 223Ra for osseous metastases, 177Lu-DOTATATE for…”
Get full text

Evaluation of PSMA-PET Biology-Guided Radiotherapy Sequential Boost to the PSMA-avid Subvolume in the Prostate Region in Low-Volume Advanced Prostate Cancer by Gaudreault, M., Chang, D., Hardcastle, N., Jackson, P., Kron, T., Hofman, M.S., Hanna, G.G., Shirvani, S.M., Siva, S.

“…Biology-guided radiation therapy (BgRT) is a new technology that aims to deliver radiation based on detecting positron emissions in real time. BgRT combined…”
Get full text

Suitability of PSMA-PET Biology-Guided Radiotherapy for Low Volume Metastases in Newly Diagnosed Prostate Cancer by Gaudreault, M., Hardcastle, N., Jackson, P., Callahan, J., Kron, T., Huntzinger, C., Shirvani, S., Da Silva, A., Hofman, M.S., Hanna, G.G., Siva, S.

Get full text

Salvage radical prostatectomy following 177Lu-PSMA-617 radioligand therapy in men with high-risk localized prostate cancer: Surgical aspects of the LuTectomy study by O’Brien, J., Alghazo, O., Buteau, J.P., Eapen, R., Jackson, P., Mitchell, C., Oon, S., Mcintosh, L., Chen, K., Jenjitranant, P., Sharma, G., Scalzo, M., Chalmers, H., Azad, A.A., Sandhu, S., Williams, S.G., Neeson, P.J., Haskali, M., Bressel, M., Kelly, B., Moon, D., Lawrentschuk, N., Hofman, M.S., Murphy, D.

Get full text

V098 - Salvage radical prostatectomy following 177Lu-PSMA-617 radioligand therapy in men with high-risk localized prostate cancer: Surgical aspects of the LuTectomy study by O’Brien, J., Alghazo, O., Buteau, J.P., Eapen, R., Jackson, P., Mitchell, C., Oon, S., Mcintosh, L., Chen, K., Jenjitranant, P., Sharma, G., Scalzo, M., Chalmers, H., Azad, A.A., Sandhu, S., Williams, S.G., Neeson, P.J., Haskali, M., Bressel, M., Kelly, B., Moon, D., Lawrentschuk, N., Hofman, M.S., Murphy, D.

Get full text

Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial by Kasivisvanathan, V., Murphy, D.G., Link, E., Lawrentschuk, N., O’Brien, J., Buteau, J.P., Roberts, M., Francis, R.J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J., Frydenberg, M., Shakher, R., Wong, L-M., Taubman, K., Lee, S.T., Hsiao, E., Nottage, M., Kirkwood, I., Iravani, A., Williams, S., Hofman, M.S.

Get full text

A1237 - Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial by Kasivisvanathan, V., Murphy, D.G., Link, E., Lawrentschuk, N., O’Brien, J., Buteau, J.P., Roberts, M., Francis, R.J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J., Frydenberg, M., Shakher, R., Wong, L-M., Taubman, K., Lee, S.T., Hsiao, E., Nottage, M., Kirkwood, I., Iravani, A., Williams, S., Hofman, M.S.

Get full text

Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA by Hofman, M.S., Sandhu, S., Eu, P., Price, J., Akhurst, T., Iravani, A., Kong, G., Ravi-Kumar, A., Williams, S., Thang, S-P., Murphy, D., Scalzo, M., Hicks, R.J., Violet, J.

Get full text

AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas by Khasraw, M., Hofman, M.S., Chantrill, L., Pavlakis, N., Gebski, V., Gill, A.J., Markman, B., Yip, S., Gibbs, E., Karapetis, C., Wong, S.F., Ransom, D.T., Michael, M., Wilson, K., Simes, J., Lipton, L.

Get full text

Using PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy by Anton, A., Ballok, Z., Bowden, P., Costello, T., Harewood, L., Corcoran, N., Dundee, P., Peters, J., Lawrentschuk, N., Troy, A., Webb, D., Chan, Y., See, A., Siva, S., Murphy, D., Hofman, M.S., Tran, B.

Get full text

523 - Prostate-specific membrane antigen positron-emission tomography (PSMA-PET) in high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) SPARTAN-like patients (pts) negative by conventional imaging by Hadaschik, B.A., Weber, M., Iravani, A., Hofman, M.S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E.J., Smith, M.R., Perez, P.M., Hope, T.A., Rauscher, I., Londhe, A., Lopez-Gitlitz, A., Cheng, S., Maurer, T., Herrmann, K., Eiber, M., Fendler, W.P.

Get full text

Prostate-specific membrane antigen positron-emission tomography (PSMA-PET) in high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) SPARTAN-like patients (pts) negative by conventional imaging by Hadaschik, B.A., Weber, M., Iravani, A., Hofman, M.S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E.J., Smith, M.R., Perez, P.M., Hope, T.A., Rauscher, I., Londhe, A., Lopez-Gitlitz, A., Cheng, S., Maurer, T., Herrmann, K., Eiber, M., Fendler, W.P.

Get full text